Replies to post #192179 on Biotech Values

[DewDiligence]

AAVL—…if the results show that one-shot isn't going to be enough but the drug otherwise shows it can meaningfully reduce the number of shots needed (compared to Lucentis) and shares tank, I think AAVL could be worth a look.

In other words, if the stocks sells off despite fairly good data, it could become a good buy. Yes, I agree with that :- )